MRK — Merck & Co., Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 310158 ·
Last close
$148.69
Market Cap
$366.84B
52W High
$156.00
52W Low
$75.80
ADV30
11,163,962
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 16,286,000,000 | 12,091,000,000 | -3,201,000,000 | -4,240,000,000 | 128,685,000,000 | 5,327,000,000 | 82,754,000,000 |
| Dec 2025 | 16,400,000,000 | 10,849,000,000 | 4,065,000,000 | 2,963,000,000 | 136,866,000,000 | 14,565,000,000 | 84,204,000,000 |
| Sep 2025 | 17,276,000,000 | 13,421,000,000 | 6,554,000,000 | 5,785,000,000 | 129,546,000,000 | 18,169,000,000 | 77,639,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$17,890,000,000
Investing CF
$-22,464,000,000
Financing CF
$852,000,000
CapEx
$-3,775,000,000
Dividends Paid
$-8,231,000,000
Buybacks
$-4,794,000,000
EPS Diluted TTM
$1.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$66,721,000,000
Inventory
$6,479,000,000
Receivables
$12,210,000,000
ST Investments
$375,000,000
EBIT TTM
$13,152,000,000
Pretax Income TTM
$11,630,000,000
Interest Exp TTM
$1,522,000,000
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,568,998,912
EBITDA
$28,871,000,064
Free Cash Flow
$15,171,500,032
Enterprise Value
$401,921,015,808
Total Cash
$7,141,000,192
Total Debt
$53,910,999,040
Shares Out
2,467,171,638
Trailing EPS
$1.25
Book Value
$16.99
ROE
7.0%
ROA
11.9%
Div Yield
2.36%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,011,000,000 | 22,107,000,000 | 18,254,000,000 | 136,866,000,000 | 84,204,000,000 | 52,606,000,000 | 16,472,000,000 |
| Dec 2024 | 64,168,000,000 | 20,221,000,000 | 17,117,000,000 | 117,106,000,000 | 70,734,000,000 | 46,313,000,000 | 21,468,000,000 |
| Dec 2023 | 60,115,000,000 | 2,954,000,000 | 365,000,000 | 106,675,000,000 | 69,040,000,000 | 37,581,000,000 | 13,006,000,000 |
| Dec 2022 | 59,283,000,000 | 18,282,000,000 | 14,519,000,000 | 109,160,000,000 | 63,102,000,000 | 45,991,000,000 | 19,095,000,000 |
TTM Snapshot
Revenues TTM
$53,137,000,000
NetIncome TTM
$12,566,000,000
OpCashFlow TTM
$0
Assets (Latest)
$117,106,000,000
Forward EPS
$9.55
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $85.00 · spot: $148.69 · call volume: 7,861 · put volume: 568
Expected Move to 2026-10-16:
±$7.80
(5.25%) —
implied range
$140.89 –
$156.49
· ATM straddle on $149.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
| NVSEF | NOVARTIS AG | $277.50B | $146.00 | — |
| AZN | ASTRAZENECA PLC | $257.68B | $166.15 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
News headlines (Yahoo Finance, 1h cache)
Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?
2026-09-29 02:11 · Yahoo
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job?
2026-09-28 23:12 · Yahoo
Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030
2026-09-28 15:26 · Yahoo
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
2026-09-28 15:23 · Yahoo
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit
2026-09-28 13:00 · Yahoo
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
2026-09-28 12:52 · Yahoo
CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
2026-09-28 12:00 · Yahoo
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
2026-09-28 10:45 · Yahoo
Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics
2026-09-28 09:03 · Yahoo
Merck Is Up 40% This Year, but Is the Keytruda Rebuild Already Priced In?
2026-09-26 15:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.